Patents Examined by Kristin Vajda
  • Asymmetric synthesis of Azaspiro compounds
    Patent number: 11401273
    Abstract: The present invention relates to an improved asymmetric synthesis of azaspiro or diazaspiro compound (hereafter referred to as the compound 5, (5A) or (5N)) or their pharmaceutically acceptable salts and derivatives; through the formation of intermediate compounds 4, (4A) or (4N) respectively. The process comprises an unusual substrate specific highly diastereoselective as well as enantio-enriched 1-substituted 2-azaspiro[3.3]heptane or 1-substituted 2-diazaspiro[3.3]heptane compounds with high diastereoselectivity by addition of a cyclobutane carboxylate anion to a Davis-Ellman's imine, followed by reduction and cyclisation resulting in the selective formation of azaspiro or diazaspiro intermediate compound 4, (4A) or (4N); which on subsequently removing the sulfinyl group provides corresponding azaspiro or diazaspiro compound 5, (5A) or (5N) respectively.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: August 2, 2022
    Assignee: PIRAMAL PHARMA LIMITED
    Inventors: Rajender Reddy Leleti, Yogesh Waman, Priya Kallure, Zubeda Begum, Thumban Divya, Kumara Swamy Nalivela, Saurabh Vijay, Paranjay Parikh, Sharadsrikar Kotturi, Chirag Patel, Krishna Nayak, Kasimraza Baharooni, Vinkal Zalavadiya
  • Apelin receptor (APJ) agonists and uses thereof
    Patent number: 11401244
    Abstract: This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: August 2, 2022
    Assignee: RESEARCH TRIANGLE INSTITUTE
    Inventors: Scott P. Runyon, Rangan Maitra, Sanju Narayanan, James Barnwell Thomas
  • Therapeutic combinations of orally administered docetaxel and a P-gp inhibitor for the treatment of cancer
    Patent number: 11389442
    Abstract: The present disclosure provides pharmaceutical combinations of orally administered docetaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered docetaxel (e.g., Taxotere® or docetaxel formulated with polysorbate 80) therapy in a subject suffering from cancer.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: July 19, 2022
    Assignee: Athenex HK Innovative Limited
    Inventors: Min-Fun Rudolf Kwan, E. Douglas Kramer, David Lawrence Cutler, Johnson Yiu-Nam Lau, Wing Kai Chan
  • Salt and solid state forms of escitalopram
    Patent number: 11390597
    Abstract: The present disclosure relates to a new salt of escitalopram and its solid state forms, processes for the preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: July 19, 2022
    Inventor: Mark Hasleton
  • Organic solvent processable carbon phosphonitride pre-polymers
    Patent number: 11390636
    Abstract: Described herein is the preparation of carbon phosphonitride pre-polymers that are soluble in organic solvents and can be further thermoset into carbon phosphonitride extended solids (i.e. films, monoliths, etc.) with an approximate empirical formula of C3N3P.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: July 19, 2022
    Assignee: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Brian L. Chaloux, Albert Epshteyn, Thomas J. Dabrow
  • Composition for preventing or treating sleep disorders
    Patent number: 11382900
    Abstract: Disclosed is a method for preventing or treating sleep disorders using TRPV1 receptor antagonist, (R)—N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide. The method of the present invention can effectively and safely prevent or treat sleep disorders accompanying pruritus caused by atopic dermatitis.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: July 12, 2022
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Gyeyoung Choi, Hyunjin Nam, Miyoung Park, Kyoungmi Jung, Jihae Lee, Chang Soon Choi, Youngho Park, Jong Hwa Roh, Eunsil Park, Jaehong Park, Kwanghyun Shin, Byoung Young Woo, Kiwha Lee, Wonkyung Cho, Joonho Choi
  • Diels-Alder reaction with furanics to obtain aromatics
    Patent number: 11384095
    Abstract: The present invention is directed to the preparation of phthalic anhydride compounds and the intermediate phthalide compounds. In particular, the invention is directed to an improved bio-based route from furanic compounds to phthalic anhydride compounds by reacting furfuryl alcohol (i.e. 2-hydroxymethylfuran) or an analogue thereof having a nucleophilic atom on the 2-methyl, with a dienophile comprising an ?,?-unsaturated carbonyl comprising an ??-leaving group. The inventions further involved preparation of phthalic anhydride compounds, phthalic acid compounds and reduction products of the intermediate phthalide compounds.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: July 12, 2022
    Assignee: Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek TNO
    Inventors: Marc Crockatt, Johan Urbanus, Pieter Cornelis Antonius Bruijnincx, Christopher Stuart Lancefield, Bart Fölker
  • Ophthalmic composition for glaucoma treatment
    Patent number: 11382887
    Abstract: An eye drop composition for treating glaucoma is disclosed. The eye drop composition includes a prostaglandin analogue, a thickening agent, and a solubilizing agent, wherein the thickening agent is carboxymethylcellulose or a salt thereof, and the solubilizing agent is tyloxapol.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: July 12, 2022
    Assignee: YS LIFE SCIENCE CO. LTD.
    Inventors: Areum Baek, Youngsik Chung, Hyun Ik Shin, Chang Young Oh, Kee Young Lee
  • Coumarin compounds and their uses as fluorescent labels
    Patent number: 11371078
    Abstract: The present application relates to new coumarin compounds and their uses as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: June 28, 2022
    Assignee: Illumina Cambridge Limited
    Inventor: Nikolai Nikolaevich Romanov
  • Antiviral agents for drug-resistant influenza A
    Patent number: 11365174
    Abstract: An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through administration of the same.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: June 21, 2022
    Assignees: Thomas Jefferson University, Ramot At Tel-Aviv University LTD.
    Inventors: Nir Ben-Tal, Roger S. Armen, Laurence C. Eisenlohr, Jitendra Belani, Michael Miller, Inbar Fish, Ori Kalid
  • Compounds and methods for inhibiting CPY26 enzymes
    Patent number: 11364220
    Abstract: Compounds described herein are inhibitors of retinoic add inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated catabolism, and are used for treating diseases that are responsive to retinoids.
    Type: Grant
    Filed: November 26, 2020
    Date of Patent: June 21, 2022
    Assignee: Queen's University at Kingston
    Inventors: Donald Andrew Cameron, Martin Petkovich, Toni Kristian Rantanen, Victor Snieckus, Johnathan Board, Suneel Singh, Ashishkumar Jayantilal Maheta
  • Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
    Patent number: 11365198
    Abstract: The present disclosure relates to pharmaceutical compositions of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and corresponding methods of treating psoriatic arthritis.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: June 21, 2022
    Assignee: AbbVie Inc.
    Inventors: Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Aileen L. Pangan, Jaclyn Kay Anderson
  • Heterocyclic amides useful as protein modulators
    Patent number: 11365190
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: June 21, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Adam Kenneth Charnley, Gren Z. Wang, Joseph J. Romano
  • Means for treating cardiovascular disease
    Patent number: 11357825
    Abstract: A means for treating cardiovascular disease, in particular chronic heart failure, especially in terms of a more specific treatment preventing or minimizing pathological hypertrophic signaling while leaving cardiac contractility largely intact. For this purpose the present invention provides a means for treating cardiovascular disease, in particular chronic heart failure, the means specifically inhibiting or causing inhibition of components of the ?1-AR/cAMP pathway generating cAMP resulting from activation of the ?1-adrenoceptor on the cardiomyocyte cell crest.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: June 14, 2022
    Assignee: Universitaetsklinikum Hamburg-Eppendorf
    Inventors: Viacheslav Nikolaev, Alexander Froese
  • Cysteamine prodrugs
    Patent number: 11357750
    Abstract: Described herein are prodrugs of cysteamine and pharmaceutically acceptable salts, solvates, and esters thereof. Also described herein are pharmaceutical compositions comprising prodrugs of cysteamine, or pharmaceutically acceptable salts, solvates, and esters thereof, and methods of treatment comprising administering prodrugs of cysteamine, or pharmaceutically acceptable salts, solvates, and esters thereof.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: June 14, 2022
    Assignee: Children's Hospital Medical Center
    Inventor: Stephen Perrett
  • Production method for dicyanocyclohexane
    Patent number: 11352318
    Abstract: The present invention provides a production method for dicyanocyclohexane, including a step of obtaining dicyanocyclohexane by reacting cyclohexanedicarboxylic acid and/or a salt thereof, or a heated concentrate of an aqueous ammonia solution of cyclohexanedicarboxylic acid with ammonia in a solvent having a boiling point equal to or higher than a reaction temperature.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: June 7, 2022
    Assignee: Mitsubishi Gas Chemical Company, Inc.
    Inventors: Akifumi Iida, Emi Nakano, Yutaka Kanbara
  • Rosin-based small molecular weight hydrogelator and its application
    Patent number: 11352317
    Abstract: The present disclosure discloses a rosin-based small molecular weight hydrogelator and an application thereof, and belongs to the fields of supramolecular chemistry, surfactant science and chemical utilization of rosin. The rosin-based small molecular hydrogel of the present disclosure can gel water at a very low concentration, and the critical gelling concentration is only 0.176 wt %. On average, each gelling agent molecule can hold 13,889 water molecules, which exhibits extremely high gel efficiency and the formed small molecular hydrogel also exhibits extremely high stability. This small molecule hydrogel is derived from the natural product rosin and has a mild nature. It can be used in the fields of drug sustained-release, tissue engineering, daily chemicals, medicine and so on.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: June 7, 2022
    Assignee: Jiangnan University
    Inventors: Binglei Song, Tingting Yan, Danping Wang, Zhenggang Cui
  • Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic ?-N-protected amino ester
    Patent number: 11345668
    Abstract: A method for the synthesis of N-protected 3,6-aminoalkyl-2,5-diketopiperazines is provided. The method includes obtaining a cyclic ?-N protected active amino ester and adding it to a mixture of an amine catalyst in an organic solvent.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: May 31, 2022
    Assignee: MANNKIND CORP.
    Inventors: John J. Freeman, Otto Phanstiel, William Elliot Bay, Kelly Sullivan Kraft
  • Process for the preparation of lifitegrast
    Patent number: 11345683
    Abstract: The present invention provides dibenzylamine salt of Lifitegrast (XV), and diphenylamine salt of Lifitegrast (XVI) and the use of the above salts in the purification process of Lifitegrast (I). The present invention relates to a process for the preparation of Lifitegrast (I).
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: May 31, 2022
    Assignee: Aurobindo Pharma Ltd
    Inventors: Praveen Kumar Neela, Guruswamy Batthini, Vijay Kumar Gupta Gangisetty, Ravikanth Dupud, Srikanth Sai Alur, Sivakumaran Meenakshisunderam
  • MAGL inhibitors
    Patent number: 11332453
    Abstract: Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: May 17, 2022
    Assignee: H. LUNDBECK A/S
    Inventors: Cheryl A. Grice, Daniel J. Buzard, Michael B. Shaghafi